Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice
Endocrinology · 2024
DOI: 10.1210/endocr/bqae069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2024. Verfasst von Guanliang Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Metabolism and Nutrition, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan. Hauptthemen laut MEDLINE: Macrophages, Mice, Inbred C57BL, Non-alcoholic Fatty Liver Disease, Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Grant-in-Aid for Scientific Research (B).
Abstract (Originalsprache)
The inhibition of hepatic macrophage and Kupfer cell recruitment and activation is a potential strategy for treating insulin resistance and nonalcoholic steatohepatitis (NASH). Cenicriviroc (CVC), a dual C-C chemokine receptor 2 (CCR2) and CCR5 antagonist, has shown antifibrotic activity in murine models of NASH and has been evaluated in clinical trials on patients with NASH. This study investigated the effects of CVC on macrophage infiltration and polarization in a lipotoxic model of NASH. C57BL/6 mice were fed a high-cholesterol, high-fat (CL) diet or a CL diet containing 0.015% CVC (CL + CVC) for 12 weeks. Macrophage recruitment and activation were assayed by immunohistochemistry and flow cytometry. CVC supplementation attenuated excessive hepatic lipid accumulation and peroxidation and alleviated glucose intolerance and hyperinsulinemia in the mice that were fed the CL diet. Flow cytometry analysis revealed that compared with the CL group, mice fed the CL + CVC diet had fewer M1-like macrophages, more M2-like macrophages, and fewer T cell counts, indicating that CVC caused an M2-dominant shift of macrophages in the liver. Similarly, CVC decreased lipopolysaccharide-stimulated M1-like macrophage activation, whereas it increased interleukin-4-induced M2-type macrophage polarization in vitro. In addition, CVC attenuated hepatic fibrosis by repressing hepatic stellate cell activation. Lastly, CVC reversed insulin resistance as well as steatosis, inflammation, and fibrosis of the liver in mice with pre-existing NASH. In conclusion, CVC prevented and reversed hepatic steatosis, insulin resistance, inflammation, and fibrogenesis in the liver of NASH mice via M2 macrophage polarization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Metabolism and Nutrition, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan.
- Jiangsu Carephar Pharmaceutical Co. Ltd., No.6 Xuzhuang Road, Xuanwu District, Nanjing 210014, Jiangsu, China.
- Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
ORCID-Profile: Mayumi Nagashimada, Liang Xu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Grant-in-Aid for Scientific Research (B)
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Chen, G., Yu, Y., Zhu, Y., Nagashimada, M., Wang, Y., Nagata, N., & Xu, L. (2024). Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice. Endocrinology. https://doi.org/10.1210/endocr/bqae069
Vancouver
Chen G, Yu Y, Zhu Y, Nagashimada M, Wang Y, Nagata N, et al. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice. Endocrinology. 2024. doi:10.1210/endocr/bqae069
BibTeX
@article{Chen2024,
author = {Chen, Guanliang and Yu, Yanwen and Zhu, Yuqin and Nagashimada, Mayumi and Wang, Yajiao and Nagata, Naoto and Xu, Liang},
title = {Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice},
journal = {Endocrinology},
year = {2024},
doi = {10.1210/endocr/bqae069}
}
EUVIMED